BroadAMP-GPT generated and experimentally tested broad-spectrum AMP_S13
BroadAMP-GPT combined transformer-based peptide generation, computational screening and experimental testing. The paper reports that 57% of AI-generated candidates showed potent activity against ESKAPE pathogens. AMP_S13 showed broad-spectrum antimicrobial activity, stability under tested conditions, low cytotoxicity and hemolysis, and efficacy in Galleria mellonella and a murine MRSA wound model. These preclinical findings do not establish human safety or efficacy; the 57% abstract metric is kept distinct from the separately reported assays of 14 synthesized candidates.
Technology: Transformer-based peptide generation with deep-learning-guided screening
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: The paper reports a 57% potent-activity rate among AI-generated candidates and describes AMP_S13 broad-spectrum activity, stability, low cytotoxicity/hemolysis, Galleria mellonella infection testing and a murine MRSA wound-infection model. A separate cohort statement reports six of 14 synthesized candidates inhibiting both E. coli and S. aureus at MIC ≤16 μg/mL; these are distinct denominators/outcomes.
- Still unknown: The results are laboratory and animal preclinical findings, not human efficacy or safety. The entry makes no claim that the peptide sequence was first disclosed here or is globally novel.
- AI role: BroadAMP-GPT generated peptide candidates with a transformer and applied deep-learning-guided screening before experimental validation; AMP_S13 is the named lead candidate in the reported assays.
Evidence sources: https://www.tandfonline.com/doi/full/10.1080/19490976.2025.2523811 · https://www.tandfonline.com/doi/pdf/10.1080/19490976.2025.2523811
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review date: 17 Nov 2026. Review scope: Primary publisher full article/PDF, publisher publication history and NCBI/PubMed metadata/abstract; first-public preprint and sequence priority are not claimed..
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.